logo

Global Clinical Trial Supply Market Size (2024 - 2029)

The clinical trial supply market is experiencing growth driven by factors such as increased R&D expenditure by pharmaceutical and biopharmaceutical companies, a rising number of registered clinical trials, and the decentralization of clinical trials. The market size is influenced by the challenges posed by COVID-19, which initially hindered clinical research activities but eventually led to a surge in trials, particularly for vaccine development. Despite these positive trends, the high costs and complexities associated with drug development, especially for rare diseases, pose challenges that could potentially slow market expansion.

Home Market Analysis Healthcare Research Biotechnology Research Bioservices Research Clinical Trial Services Research Global Clinical Trial Supply Market Market Size

Market Size of Global Clinical Trial Supply Industry

Clinical Trial Supply Market Size
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 6.50 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Clinical Trial Supply Market Size

*Disclaimer: Major Players sorted in no particular order

Clinical Trial Supply Market Analysis

The clinical trial supply market is expected to register a CAGR of 6.5% over the forecast period, 2022-2027.

COVID-19 has affected almost every sector and so had a substantial effect on clinical research activities across the globe. The lockdown imposed by the government has created challenges and obstacles for clinical research studies as many clinical research organizations were not able to initiate new trials, which led to difficulties in recruiting new subjects and experiencing lower follow-up rates in the ongoing clinical trials. However, over a few months, the trials which had been pushed aside due to COVID-19 had gained significant traction. For instance, in the journal Clinical Pharmacology and Therapeutics 2022 an article titled, 'The impact of COVID-19 in the initiation of clinical trials in Europe and the United States' summarizes that the United States reported a 3% increase in overall clinical trials studies while European countries showed the overall increase of 10% in clinical trials studies. Although COVID-19 has affected the non-COVID-19 clinical trials in the United States and Europe, the emergence of COVID-19 led to the development of many new vaccines launched by various companies, which directly increased the overall number of clinical trials in the year 2020 as compared to 2019.

Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies, increasing number of registered clinical trials, and increasing decentralization of clinical trials are some of the key factors driving the market growth. The spending on the R&D market and the introduction of new drugs have increased in the past two decades. For instance, an article published in Congressional Budget Office, 2021 reports that in the year 2019, the pharmaceutical industry spent 83 billion dollars on R&D, this amount was 10 times what the industry used to spend in the 1980s. Additionally, the number of new drug approval increased up to 60% between 2010 to 2020, with a peak of 50 novel approval of drugs by the Food and Drug Administration (FDA) in 2021.

The increasing number of registered clinical trials had a direct impact on driving the clinical trial supply market. For instance, as per the data reported on the clinicaltrials.gov site, in June 2022, the total number of clinical trial studies globally reported was 419,487 while 2,119 were registered clinical trials in 2000. The increase in expenditure in the R&D market has boosted the novel drug development process, which has boosted the number of clinical trials, thereby driving the clinical trials supply market.

Due to the high cost of the drug development market and research for some rare diseases are very challenging and requires a specific group of people to conduct a clinical trial, the chances for the failure of clinical trials for such studies are quite high, which may slow down the growth of this market.

Clinical Trial Supply Industry Segmentation

As per the scope of this report, clinical trial supply is defined as the supply of materials required for conducting a clinical trial and this includes 24-hour collection and delivery of biological, etc. The Clinical Trial Supply Market is segmented by Clinical Phase (Phase 1, Phase 2, Phase 3, and Others), Services (Manufacturing, Storage and Distribution, and Supply Chain Management), Application (Oncology, Central Nervous System, Infectious Diseases, Metabolic Disorder, Cardiovascular and Others), End-User (Pharmaceuticals, Biologics, Medical Devices, and Others), Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Need A Different Region Or Segment?
Customize Now

Global Clinical Trial Supply Market Size Summary

The clinical trial supply market is poised for growth, driven by increasing research and development expenditures in the pharmaceutical and biopharmaceutical sectors, alongside a rising number of registered clinical trials. The market has shown resilience despite challenges posed by the COVID-19 pandemic, which initially disrupted clinical research activities but eventually led to an increase in trials, particularly for vaccine development. The decentralization of clinical trials and the introduction of novel drugs have further propelled market expansion. However, the high costs and complexities associated with drug development, especially for rare diseases, pose challenges that could potentially slow market growth. The market is characterized by a fragmented landscape with numerous global and regional players, including major companies like Thermo Fisher Scientific, Catalent, and Parexel.

Biologics and biosimilars are expected to experience steady growth due to their complex manufacturing processes and increasing research activities in genetics and biotechnology. The widespread use of biologics for advanced therapies, particularly in cancer treatment, is driving their market expansion. North America leads the clinical trial supply market, supported by technological advancements, government funding, and a high incidence of diseases, particularly cancer. The region's robust regulatory framework and concentration of pharmaceutical leaders contribute to its dominance. The market's competitive landscape is marked by collaborations and innovations aimed at enhancing clinical trial processes, such as the partnership between Thermo Fisher Scientific and Matrix Clinical Trials to implement decentralized trial solutions.

Explore More

Global Clinical Trial Supply Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing R&D expenditure of pharmaceutical and biopharmaceutical companies

      2. 1.2.2 Increasing number of registered clinical trials

      3. 1.2.3 Increasing decentralization of clinical trials

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Drug Development

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 Clinical Phase Type

      1. 2.1.1 Phase 1

      2. 2.1.2 Phase 2

      3. 2.1.3 Phase 3

      4. 2.1.4 Others

    2. 2.2 Product Type

      1. 2.2.1 Manufacturing

      2. 2.2.2 Storage and Distribution- Cold Chain Based/Non-Cold Chain Based

      3. 2.2.3 Supply Chain Management

    3. 2.3 End-Users

      1. 2.3.1 Pharmaceuticals

      2. 2.3.2 Biologics

      3. 2.3.3 Medical Devices

      4. 2.3.4 Others

    4. 2.4 Application

      1. 2.4.1 Oncology

      2. 2.4.2 CNS

      3. 2.4.3 Infectious Disease

      4. 2.4.4 Metabolic Disorder

      5. 2.4.5 Cardiovascular

      6. 2.4.6 Others

    5. 2.5 Geography

      1. 2.5.1 North America

        1. 2.5.1.1 United States

        2. 2.5.1.2 Canada

        3. 2.5.1.3 Mexico

      2. 2.5.2 Europe

        1. 2.5.2.1 Germany

        2. 2.5.2.2 United Kingdom

        3. 2.5.2.3 France

        4. 2.5.2.4 Italy

        5. 2.5.2.5 Spain

        6. 2.5.2.6 Rest of Europe

      3. 2.5.3 Asia-Pacific

        1. 2.5.3.1 China

        2. 2.5.3.2 Japan

        3. 2.5.3.3 India

        4. 2.5.3.4 Australia

        5. 2.5.3.5 South Korea

        6. 2.5.3.6 Rest of Asia-Pacific

      4. 2.5.4 Middle East and Africa

        1. 2.5.4.1 GCC

        2. 2.5.4.2 South Africa

        3. 2.5.4.3 Rest of Middle East and Africa

      5. 2.5.5 South America

        1. 2.5.5.1 Brazil

        2. 2.5.5.2 Argentina

        3. 2.5.5.3 Rest of South America

Global Clinical Trial Supply Market Size FAQs

The Global Clinical Trial Supply Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)

Thermo Fisher Scientific, Catalent, Paraxel, Almac Group and Marken are the major companies operating in the Global Clinical Trial Supply Market.

Global Clinical Trial Supply Report Snapshots

Clinical Trial Supply Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)